Anti-leishmanial Nanotherapeutics: A Current Perspective
-
Published:2019-07-17
Issue:6
Volume:20
Page:473-482
-
ISSN:1389-2002
-
Container-title:Current Drug Metabolism
-
language:en
-
Short-container-title:CDM
Author:
Shah Aditi1, Gupta Souvik Sen1
Affiliation:
1. Division of Biological and Life Sciences, School of Arts and Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad, Gujarat -380009, India
Abstract
Background:
Leishmaniasis is a dreaded disease caused by protozoan parasites belonging to the genus
Leishmania which results in significant morbidity and mortality worldwide. There are no vaccines available currently
for the treatment of Leishmaniasis and chemotherapy still remains the mainstay for anti-leishmanial therapeutics.
However, toxicity, reduced bioavailability, high cost and chemoresistance are the principal problems which limit the
use of the available drugs. In this context, anti-leishmanial nanotherapeutics may show the way for effective treatment
of this dreaded disease.
Methods:
We carried out extensive literature search of bibliographic database using keywords strictly within the
scope of the present study for peer reviewed research articles. We focused specifically on articles related to the application
of nanotechnology in drug development, drug delivery and vaccine delivery for anti-leishmanial therapeutics.
Results:
This study shows the immense potential of the application of nanotechnology in the field of anti-leishmanial
therapeutics. This will aid the targeted delivery of different drugs which is expected to increase the bioavailability,
reduce toxicity and also address the problem of chemoresistance.
Conclusion:
We surmise that exciting research in the field of anti-leishmanial nanotherapeutics is already showing
the promise for effective applicability. Though direct use of nanoparticles as therapeutic agents does not seem to be a
good option, the application of nanotechnology in this field for vaccine development is still in its early days. The
nano based drug delivery system for anti-leishmanial therapeutics has evolved considerably over the past ten years
and holds the potential to drastically change the landscape of anti-leishmanial therapeutics.
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference73 articles.
1. . Separ Purif Tech, ,, , 166,, 230-,World Health Organization, Leishmaniasis, 2018 (Accessed May 16, ). 2. . About Leishmaniasis, 2018, Drugs for Neglected Diseases initiative,,, , 166,, 230-, (Accessed May 16, ). 3. Desjeux P. Comp Immunol Microbiol Infect Dis, Leishmaniasis: Current situation and new perspectives.,, 2004, 27,, 305-318, 4. Bhargava P, Singh R. Interdiscip Perspect Infect Dis, Developments in diagnosis and antileishmanial drugs.,, 2012, 2012,, 305-, 5. Cupolillo E, Brahim LR, Toaldo CB, De Oliveira-Neto MP, De Brito ME, Falqueto A, De Farias Naiff M, Grimaldi G. J Clin Microbiol, Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil.,, 2003, 41,, 3126-3132,
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|